pruritus, jeuk burns, brandwonden
Conditions
Interventions
Patients will be randomised between:
1. Doxepin hydrochloride 5% cream, placebo tablets
2. Placebo cream, clemastine 1 mg tablets.
Treatment will be given as long as the complaints persist.
Sponsors
Association of Dutch Burn Centres
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. Patients with healed burns and itch; 2. Itch intensity as assessed by VAS score greater than or equal to 3; 3. Patients treated in one of the three Dutch burn centres; 4. Patients aged 18 years or older.
Exclusion criteria
Exclusion criteria: An eligible subject who meets any of the following criteria will be excluded from participation in this study: 1. Inability to give informed consent by patient or legal representatives; 2. Inability to understand and fill in VAS scores and quality of life/pruritus assessment questionnaires, as judged by the treating physician; 3. Known pregnancy or breast-feeding; 4. (Active) cutaneous or systemic disease causing itch; 5. Any disease or condition which, according to the physician's judgement, is associated with adverse effects using doxepin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate whether doxepin hydrochloride 5% cream is more effective in reducing pruritus in patients with burns than standard treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate whether patients treated with doxepin hydrochloride 5% cream compared to standard treatment: 1. Have a better quality of life; 2. Have less erythematous scars. | — |
Contacts
Public ContactH.C. Kuipers
Association of Dutch Burn Centres Burn Center Martini Hospital Van Swietenplein 1
Outcome results
None listed